Abraham Scaria
Chief Scientific Officer Beacon Therapeutics
Abraham brings 25 years of experience in gene therapy, ranging from discovery research to early-stage clinical trials.
Most recently, he was Chief Scientific Officer at AGTC leading the ophthalmology & neuroscience research programs. Prior to that, Abraham was Chief Science Officer at IVERIC Bio. Before his tenure at IVERIC Bio, he served as Vice President and Head of Ophthalmology/Gene Editing at Casebia Therapeutics, where he built out the ophthalmology R&D group from the ground-up. Prior to Casebia, he served as the Head of Gene Therapy Research at Sanofi Genzyme, where he was responsible for all aspects of gene therapy discovery and pre-clinical research. Abraham earned his Ph.D. in molecular biology at the Indiana University School of Medicine followed by post-doctoral training at St. Louis University School of Medicine and at University of Washington School of Medicine.
Seminars
- Compare intravitreal AAV delivery for secreted proteins versus subretinal surgery for intracellular targets, understanding which retinal cell populations each route can effectively transduce
- Explore emerging suprachoroidal gene therapy delivery that may offer a middle ground between surgical complexity and transduction efficiency for RPE and photoreceptor targets
- Evaluate novel capsid engineering strategies that enable efficient transduction from the vitreous while minimizing dose-dependent inflammation
